BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 20864317)

  • 1. A novel immunotherapeutic approach to melanoma-bearing hosts with protein-transduction domain-containing immunogenic foreign antigens.
    Kanzaki M; Okamoto T; Mitsui H; Shibagaki N; Shimada S
    J Dermatol Sci; 2010 Nov; 60(2):84-94. PubMed ID: 20864317
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intradermal injections of polyarginine-containing immunogenic antigens preferentially elicit Tc1 and Th1 activation and antitumour immunity.
    Mitsui H; Okamoto T; Kanzaki M; Inozume T; Shibagaki N; Shimada S
    Br J Dermatol; 2010 Jan; 162(1):29-41. PubMed ID: 19863514
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting dendritic cells with antigen-containing liposomes: a highly effective procedure for induction of antitumor immunity and for tumor immunotherapy.
    van Broekhoven CL; Parish CR; Demangel C; Britton WJ; Altin JG
    Cancer Res; 2004 Jun; 64(12):4357-65. PubMed ID: 15205352
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antigen-presenting cells pulsed with unfractionated tumor-derived peptides are potent tumor vaccines.
    Nair SK; Boczkowski D; Snyder D; Gilboa E
    Eur J Immunol; 1997 Mar; 27(3):589-97. PubMed ID: 9079797
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dendritic cells transduced with TAT protein transduction domain-containing tyrosinase-related protein 2 vaccinate against murine melanoma.
    Shibagaki N; Udey MC
    Eur J Immunol; 2003 Apr; 33(4):850-60. PubMed ID: 12672050
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gene transfer of AIMP1 and B7.1 into epitope-loaded, fibroblasts induces tumor-specific CTL immunity, and prolongs the survival period of tumor-bearing mice.
    Kim TS; Lee BC; Kim E; Cho D; Cohen EP
    Vaccine; 2008 Nov; 26(47):5928-34. PubMed ID: 18793691
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Deoxyribonucleic acid (DNA) encoding a pan-major histocompatibility complex class II peptide analogue augmented antigen-specific cellular immunity and suppressive effects on tumor growth elicited by DNA vaccine immunotherapy.
    Teramoto K; Kontani K; Ozaki Y; Sawai S; Tezuka N; Nagata T; Fujino S; Itoh Y; Taguchi O; Koide Y; Asai T; Ohkubo I; Ogasawara K
    Cancer Res; 2003 Nov; 63(22):7920-5. PubMed ID: 14633722
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dendritic cell-based genetic immunization in mice with a recombinant adenovirus encoding murine TRP2 induces effective anti-melanoma immunity.
    Tüting T; Steitz J; Brück J; Gambotto A; Steinbrink K; DeLeo AB; Robbins P; Knop J; Enk AH
    J Gene Med; 1999; 1(6):400-6. PubMed ID: 10753065
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An essential role of antigen-presenting cell/T-helper type 1 cell-cell interactions in draining lymph node during complete eradication of class II-negative tumor tissue by T-helper type 1 cell therapy.
    Chamoto K; Wakita D; Narita Y; Zhang Y; Noguchi D; Ohnishi H; Iguchi T; Sakai T; Ikeda H; Nishimura T
    Cancer Res; 2006 Feb; 66(3):1809-17. PubMed ID: 16452242
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapy of murine tumors with recombinant Bordetella pertussis adenylate cyclase carrying a cytotoxic T cell epitope.
    Fayolle C; Ladant D; Karimova G; Ullmann A; Leclerc C
    J Immunol; 1999 Apr; 162(7):4157-62. PubMed ID: 10201941
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetically engineered fibroblasts with antigen-presenting capability: efficient induction of an antigen-specific cytotoxic T-lymphocyte response and protection against tumor development in vivo.
    Kim TS; Chung SW; Kim SH; Kang BY; Hwang SY; Lee JW
    Cancer Gene Ther; 2000 Jun; 7(6):861-9. PubMed ID: 10880016
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of mouse MAGE-derived H-2Kb-restricted CTL epitopes.
    Eggert AO; Andersen MH; Voigt H; Schrama D; Kämpgen E; Straten PT; Becker JC
    Eur J Immunol; 2004 Nov; 34(11):3285-90. PubMed ID: 15384049
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A retrogen strategy for presentation of an intracellular tumor antigen as an exogenous antigen by dendritic cells induces potent antitumor T helper and CTL responses.
    You Z; Hester J; Rollins L; Spagnoli GC; van der Bruggen P; Chen SY
    Cancer Res; 2001 Jan; 61(1):197-205. PubMed ID: 11196161
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nonspecific CD4(+) T cells with uptake of antigen-specific dendritic cell-released exosomes stimulate antigen-specific CD8(+) CTL responses and long-term T cell memory.
    Hao S; Yuan J; Xiang J
    J Leukoc Biol; 2007 Oct; 82(4):829-38. PubMed ID: 17626150
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunotherapeutic potential of tumor antigen-pulsed and unpulsed dendritic cells generated from murine bone marrow.
    Yang S; Darrow TL; Vervaert CE; Seigler HF
    Cell Immunol; 1997 Jul; 179(1):84-95. PubMed ID: 9259775
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High avidity CTLs for two self-antigens demonstrate superior in vitro and in vivo antitumor efficacy.
    Zeh HJ; Perry-Lalley D; Dudley ME; Rosenberg SA; Yang JC
    J Immunol; 1999 Jan; 162(2):989-94. PubMed ID: 9916724
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adoptive transfer of type 1 CTL mediates effective anti-central nervous system tumor response: critical roles of IFN-inducible protein-10.
    Nishimura F; Dusak JE; Eguchi J; Zhu X; Gambotto A; Storkus WJ; Okada H
    Cancer Res; 2006 Apr; 66(8):4478-87. PubMed ID: 16618775
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Generation of a prophylactic melanoma vaccine using whole recombinant yeast expressing MART-1.
    Riemann H; Takao J; Shellman YG; Hines WA; Edwards CK; Franzusoff A; Norris DA; Fujita M
    Exp Dermatol; 2007 Oct; 16(10):814-22. PubMed ID: 17845213
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction of an antigen cascade by diversified subcutaneous/intratumoral vaccination is associated with antitumor responses.
    Kudo-Saito C; Schlom J; Hodge JW
    Clin Cancer Res; 2005 Mar; 11(6):2416-26. PubMed ID: 15788693
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Primary T-cell and activated macrophage response associated with tumor protection using peptide/poly-N-acetyl glucosamine vaccination.
    Maitre N; Brown JM; Demcheva M; Kelley JR; Lockett MA; Vournakis J; Cole DJ
    Clin Cancer Res; 1999 May; 5(5):1173-82. PubMed ID: 10353754
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.